

NCTN Adolescent and Young Adult (AYA) Cancer Trials Portfolio (Updated on 1/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

Newly Diagnosed Disease	Recurrent Disease
<div>Osteosarcoma (Pulmonary mets)</div> <div>AOST2031</div>	<div>Precursor B-Lymphoblastic Leukemia (B-Cell ALL)</div> <div>AALL1821</div>
<div>Osteosarcoma (High Grade)</div> <div>AOST2032</div>	<div>Osteosarcoma (Pulmonary mets)</div> <div>AOST2031</div>
<div>Classical Hodgkin Lymphoma</div> <div>AHOD2131</div>	<div>Precursor T-Lymphoblastic Leukemia/ Lymphoma (T-Cell ALL/LBL) - MRD</div> <div>EA9213</div>
<div>Invasive breast carcinoma (HR+/HER2-)</div> <div>NRG-BR009 (OFSET)*^</div>	<div>Precursor T-Lymphoblastic Leukemia/ Lymphoma (T-Cell ALL/LBL)</div> <div>S1905</div>
<div>Germ Cell Tumors</div> <div>AGCT1531</div> <div>AGCT1532</div>	<div>Adrenocortical Carcinoma</div> <div>A092204</div>
<div>Precursor B-Lymphoblastic Leukemia (B-Cell ALL)</div> <div>A041501*</div>	<div>Adrenocortical Carcinoma</div> <div>A092204</div>

Legend by Disease Types

Green =
Osteosarcoma

Orange =
Hodgkin
Lymphoma

Purple =
Breast

Yellow =
Germ Cell
Tumors

Blue =
B-Cell ALL

Light Green =
Adrenocortical
Carcinoma

Light Blue =
T-Cell ALL /
T-Cell LBL

Note: * NRG-BR009 and A041501: Age 18 years and older; ^ NRG-BR009: COG is not directly participating.

NCTN Adolescent and Young Adult (AYA) Cancer Trials (Open as of 1/15/2026)

Protocol Number	Phase	Protocol Title
A041501	III	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
A092204	II	A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer
AALL1821	II	A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >= 1 to < 31 Years Old with First Relapse
AGCT1531	III	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532	III	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
AHOD2131	III	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
AOST2031	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
AOST2032	II/III	A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
EA9213	II	A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score <= 25 (OFSET)
S1905	I/II	A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)